News | July 04, 2021
Laurus receives license to manufacture and market 2DG
2DG has been given emergency approval by the Drug Controller General of India (DCGI) for use on COVID-19 patients in the country
2DG has been given emergency approval by the Drug Controller General of India (DCGI) for use on COVID-19 patients in the country
2DG has been given emergency approval by the Drug Controller General of India for COVID-19 patients in the country
The company has launched Perampil, at 2 mg (Rs. 49/strip of 7 tablets), 4 mg (Rs. 180/strip of 15 tablets) and 6 mg (Rs. 300/strip of 15 tablets) to improve patient access
Sun Pharma is granted rights for co-marketing of the drug in India in the private market under the brand name CARITEC
BALflu is approved by DCGI for emergency use for the treatment of COVID-19
The product patent has been already filed under fast track approval
The COVID Working Group has recommended extension of the gap between the first and second doses of Covishield
Proactively engaging with foreign vaccine manufacturers like Moderna, Pfizer etc., to apply for Emergency Use Authorization in India so that these vaccines can be easily imported and made available in India
BBIL had proposed to carry out Phase II/III clinical trial of Covaxin in the age group of 2 to 18 years
Seven manufacturers of Remdesivir have increased production capacity to 1.03 crore vials per month up from 38 lakh vials per month a month ago
Subscribe To Our Newsletter & Stay Updated
